Under the agreement, NovaRhythm obtains exclusive global rights to progress the molecule through IND-enabling studies, clinical development and commercialization, with a primary objective of ...
Medtronic (NYSE:MDT) today announced CE mark approval and the first commercial European implants for its OmniaSecure system.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果